SAB Biotherapeutics (SABS) Enterprise Value (QoQ) (2021 - 2026)
SAB Biotherapeutics (SABS) Enterprise Value (QoQ) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.18% |
| Dec 31, 2025 | 12.89% |
| Sep 30, 2025 | -1,840.66% |
| Jun 30, 2025 | 55.54% |
| Mar 31, 2025 | 38.10% |
| Dec 31, 2024 | 31.71% |
| Sep 30, 2024 | 18.46% |
| Jun 30, 2024 | 15.37% |
| Mar 31, 2024 | 22.11% |
| Dec 31, 2023 | -2,232.16% |
| Sep 30, 2023 | 68.80% |
| Jun 30, 2023 | 40.47% |
| Mar 31, 2023 | 13.20% |
| Dec 31, 2022 | -80.59% |
| Sep 30, 2022 | 49.86% |
| Jun 30, 2022 | 25.85% |
| Mar 31, 2022 | 43.33% |
| Dec 31, 2021 | -267.83% |
| Sep 30, 2021 | -5.06% |
| Jun 30, 2021 | 49.16% |